Literature DB >> 32033757

Burden of Disease due to Nonalcoholic Fatty Liver Disease.

Mark D Muthiah1, Arun J Sanyal2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease in both Western populations and other parts of the world. This review discusses the prevalence and incidence of NAFLD in various regions around the world. The methodology used to identify the epidemiology and classify the stages of the disease is described. The impact of the disease on individuals, looking at both liver-related and extrahepatic consequences of the disease, is then discussed. Finally, the economic and societal impact of the disease is discussed.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Burden of disease; Epidemiology; Incidence; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Prevalence

Year:  2020        PMID: 32033757     DOI: 10.1016/j.gtc.2019.09.007

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  10 in total

1.  Serum Level of Alanine- and Aspartate-Aminotransferase Levels in Newborns in India.

Authors:  Nanda Chhavi; Sachi Ojha; Ashish Awasthi; Amit Goel
Journal:  J Clin Exp Hepatol       Date:  2021-09-23

2.  Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis.

Authors:  Chloe Wong; Clyve Yu Leon Yaow; Cheng Han Ng; Yip Han Chin; Yi Fen Low; Amanda Yuan Ling Lim; Mark Dhinesh Muthiah; Chin Meng Khoo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-11       Impact factor: 5.555

Review 3.  Retinoids in the Pathogenesis and Treatment of Liver Diseases.

Authors:  Marta Melis; Xiao-Han Tang; Steven E Trasino; Lorraine J Gudas
Journal:  Nutrients       Date:  2022-03-31       Impact factor: 5.717

4.  Endothelial-immune crosstalk contributes to vasculopathy in nonalcoholic fatty liver disease.

Authors:  Chun-Yi Ng; Khang Leng Lee; Mark Dhinesh Muthiah; Kan Xing Wu; Florence Wen Jing Chioh; Konstanze Tan; Gwyneth Shook Ting Soon; Asim Shabbir; Wai Mun Loo; Zun Siong Low; Qingfeng Chen; Nguan Soon Tan; Huck Hui Ng; Yock Young Dan; Christine Cheung
Journal:  EMBO Rep       Date:  2022-04-11       Impact factor: 9.071

5.  Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning.

Authors:  Mazen Noureddin; Fady Ntanios; Deepa Malhotra; Katherine Hoover; Birol Emir; Euan McLeod; Naim Alkhouri
Journal:  Hepatol Commun       Date:  2022-04-01

6.  Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality.

Authors:  Cheng Han Ng; Zhen Yu Wong; Nicholas W S Chew; Kai En Chan; Jieling Xiao; Nilofer Sayed; Wen Hui Lim; Darren Jun Hao Tan; Ryan Wai Keong Loke; Phoebe Wen Lin Tay; Jie Ning Yong; Gywneth Kong; Daniel Q Huang; Jiong-Wei Wang; Mark Chan; Mayank Dalakoti; Nobuharu Tamaki; Mazen Noureddin; Mohammad Shadab Siddiqui; Arun J Sanyal; Mark Muthiah
Journal:  Front Cardiovasc Med       Date:  2022-08-08

7.  Changing trends in the air pollution-related disease burden from 1990 to 2019 and its predicted level in 25 years.

Authors:  Wan Hu; Lanlan Fang; Hengchuan Zhang; Ruyu Ni; Guixia Pan
Journal:  Environ Sci Pollut Res Int       Date:  2022-08-03       Impact factor: 5.190

Review 8.  Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe?

Authors:  Jiajia Chen; Xiaoyi Deng; Yongjian Liu; Qiuhua Tan; Guidong Huang; Qishi Che; Jiao Guo; Zhengquan Su
Journal:  Int J Biol Sci       Date:  2020-06-23       Impact factor: 6.580

Review 9.  Recent Epidemiology of Nonalcoholic Fatty Liver Disease.

Authors:  Soumya Murag; Aijaz Ahmed; Donghee Kim
Journal:  Gut Liver       Date:  2021-03-15       Impact factor: 4.519

10.  Vitamin A in Nonalcoholic Fatty Liver Disease: A Key Player in an Offside Position?

Authors:  Carmen Berasain; Matias A Avila
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2020-09-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.